Eased Tensions On Korean Peninsula To Fuel Botanical Drug R&D?
Herbal-derived drug development on the Korean peninsula is poised to get an initial boost once the relationship between the North and South improves, although it is uncertain how the possible easing of tensions between the two countries will broadly affect South Korea's pharma sector.
You may also be interested in...
As political talks gain momentum, the Kaesong Industrial Complex in North Korea could be the starting point of possible healthcare cooperation with the South, once the relationship between the two countries improves, a South Korean official report suggests.
Dong-A makes notable progress in botanical drug programs, reaching deals for its diabetic neuropathic pain and Alzheimer's disease drug assets with Boston-based NeuroBo Pharmaceuticals.
Plus deals involving Novo Nordisk/Neomorph, Mabwell/Jiangsu Haibo, Alteogen/Merck & Co., Gilead/Biocytogen, AlphaGen/ARTBIO and XOMA/Kinnate.